Founded in 1976, Helsinn is a family-run pharmaceutical group with a global focus.
Led by Riccardo Braglia, Group Vice Chairman and CEO, Giorgio Calderari, Group General Manager and COO, and an outstanding management team committed to Helsinn's core values, the Group develops innovative solutions to improve the lives of people with cancer - each year investing approximately 25% of its profits in R&D.
All of Helsinn's output is guided and underpinned by core family values of quality, integrity, and respect. This ethos, along with strong alliances with worldwide partners who share Helsinn's values, has helped the Group to develop new treatments to fulfil more medical needs across 190 countries.
Helsinn is accredited as a sustainable company and since its inception has grown to over 700 employees in Switzerland, USA, Ireland, Monaco and China.
Helsinn launched an investment fund in 2016 to support the future of innovation in healthcare and advance early-stage opportunities: providing funding and strategic support to innovative healthcare companies and assets.
This commitment to advancing patient care and supporting innovation in healthcare, rooted in strong community values, makes Helsinn a Swiss Biotech Success Story.